1. Articles in category: Treatment

    1-24 of 195 1 2 3 4 5 6 7 8 9 »
    1. Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Neuroblastoma: clinical and biological approach to risk stratification and treatment.

      Cell Tissue Res. 2018 Mar 23;:

      Authors: Tolbert VP, Matthay KK

      Abstract Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most common in the first year of life.

      Read Full Article
      Mentions: Treatment MYCN
    2. Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma.

      Korean J Pediatr. 2018 Feb;61(2):53-58

      Authors: Kim C, Choi YB, Lee JW, Yoo KH, Sung KW, Koo HH

      Abstract Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen.

      Read Full Article
    3. Study identifies two new biomarkers for common form of childhood cancer

      Study identifies two new biomarkers for common form of childhood cancer

      Two new biomarkers for a type of cancer in children called neuroblastoma have been identified in a study published in the journal Cancer Cell. The findings are expected to have immediate significance for disease prognosis, and eventually also for treatment. "There is a need for new methods of ...

      Read Full Article
    4. Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Updates in Diagnosis, Management, and Treatment of Neuroblastoma.

      Radiographics. 2018 Mar-Apr;38(2):566-580

      Authors: Swift CC, Eklund MJ, Kraveka JM, Alazraki AL

      Abstract Neuroblastoma is an embryonic tumor of the peripheral sympathetic nervous system. It is the most common extracranial solid tumor of childhood and accounts for up to 15% of all pediatric cancer fatalities.

      Read Full Article
      Mentions: Treatment
    5. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.

      A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.

      Cell Death Differ. 2018 Mar 07;:

      Authors: Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I

      Read Full Article
      Mentions: Treatment ALK
    6. A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      A rare mediastinal occurrence of neuroblastoma in an adult: case report.

      Sao Paulo Med J. 2018 Mar 05;:0

      Authors: Yanik F, Karamustafaoglu YA, Yoruk Y

      Abstract CONTEXT: Neuroblastoma is the most common extracranial malignant solid tumor that occurs during childhood. It arises from primitive cells and is seen in the adrenal medulla and sympathetic ganglia of the sympathetic nervous system.

      Read Full Article
    7. Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo.

      Exp Cell Res. 2018 Feb 27;:

      Authors: Xu DQ, Toyoda H, Yuan XJ, Qi L, Chelakkot VS, Morimoto M, Hanaki R, Kihira K, Hori H, Komada Y, Hirayama M

      Abstract Neuroblastoma (NB) is one of the most common solid tumors in children. High-risk NB remains lethal in about 50% of patients despite comprehensive and intensive treatments.

      Read Full Article
    8. Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Targeted Doxorubicin-loaded Bacterially Derived Nano-cells for the Treatment of Neuroblastoma.

      Mol Cancer Ther. 2018 Feb 28;:

      Authors: Sagnella SM, Trieu J, Brahmbhatt H, MacDiarmid JA, MacMillan A, Whan RM, Fife CM, McCarroll JA, Gifford AJM, Ziegler DS, Kavallaris M

      Read Full Article
      Mentions: Treatment
    9. Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma.

      Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma.

      J Control Release. 2018 Feb 23;:

      Authors: Sama S, Woith E, Walther W, Jerz G, Chen W, Hart S, Melzig MF, Weng A

      Abstract Neuroblastoma represents the third most common malign neoplasm occurring in children and the most common in newborn.

      Read Full Article
    10. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.

      Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.

      J Pediatr Surg. 2018 Jan 31;:

      Authors: Frommann K, Appl B, Hundsdoerfer P, Reinshagen K, Eschenburg G

      Abstract PURPOSE: In spite of good initial therapy response neuroblastomas often spread to distant organs or relapse after periods of remission.

      Read Full Article
      Mentions: Treatment Relapse
    11. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    12. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    13. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    14. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN

      Read Full Article
      Mentions: Antibody Treatment
    15. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients. Here, we investigated the inflammatory response and treatment tolerance of long-term infusion (LTI) of ch14.18/CHO (10 × 10 mg/m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program.

      Read Full Article
      Mentions: Antibody Treatment
    16. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Cancer Gene Ther. 2016 Nov;23(11):371-372

      Authors: Mohammadi M, Goodarzi M, Jaafari MR, Mirzaei HR, Mirzaei H

      Abstract Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB.

      Read Full Article
    17. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    18. FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      Oncotarget. 2017 Dec 15;8(66):109985-109999

      Authors: Lange I, Espinoza-Fuenzalida I, Ali MW, Serrano LE, Koomoa DT

      Abstract Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression.

      Read Full Article
    19. mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      ACS Appl Mater Interfaces. 2018 Jan 03;:

      Authors: Haimov E, Weitman H, Polani S, Schori H, Zitoun D, Shefi O

      Abstract Photodynamic Therapy (PDT) is a promising therapeutic modality for cancer. However, current protocols using bare drugs suffer from several limitations that impede its beneficial clinical effects. Here, we introduce a new approach for an efficient PDT treatment.

      Read Full Article
    20. Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance.

      Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance.

      PLoS One. 2018;13(1):e0189711

      Authors: Abou-Antoun TJ, Nazarian J, Ghanem A, Vukmanovic S, Sandler AD

      Read Full Article
      Mentions: Treatment MYCN
    21. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      The European Commission has...

      Read Full Article
    22. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Oncotarget. 2017 Dec 05;8(63):106820-106832

      Authors: Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K

      Abstract Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.

      Read Full Article
      Mentions: Treatment ALK MYCN
    23. Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Indian J Med Res. 2017 Aug;146(2):216-223

      Authors: Seth R, Singh A, Seth S, Sapra S

      Abstract BACKGROUND & OBJECTIVES: With improved survival of childhood cancer patients, the number of long-term cancer survivors is increasing. Some studies have assessed the long-term morbidity after childhood cancer treatment in the developing countries.

      Read Full Article
    1-24 of 195 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles